

### **AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claim 1. (Currently amended) A sense oligoribonucleotide, an antisense oligoribonucleotide or a double stranded RNA comprising said sense and antisense oligoribonucleotides, wherein the sense oligoribonucleotide is substantially identical to less than 23 contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 1 (human StAR binding protein gene) and targets contains bases 187-205 or 474-494 of SEQ ID NO: 1.

Claim 2. (Currently amended) The ~~sense oligoribonucleotide, the antisense oligoribonucleotide or the~~ double stranded RNA comprised thereof as in claim 1, wherein said oligoribonucleotide [[is]] targets bases 187-205 or 474-494 of SEQ ID NO: 1.

Claims 3-4. (Canceled)

Claim 5. (New) A method for inhibiting expression of SBP gene in cancer cells, comprising introducing into cancer cells *in vitro* the sense oligoribonucleotide, the antisense oligoribonucleotide or the double stranded RNA comprised thereof as in claim 1.

Claim 6. (New) A kit for cancer therapy comprising:

- (1) the sense oligoribonucleotide, the antisense oligoribonucleotide or the double stranded RNA comprised thereof as in claim 1; and

Attorney Docket No.: 47232.5006/00US  
U.S. Application No.: 10/565,283  
Amendment Dated: September 13, 2007  
Reply to Office Action: June 13, 2007

- (2) a component useful for introducing the sense oligoribonucleotide, the antisense oligoribonucleotide or the double stranded RNA into a cancer cell *in vitro*.